GGrantIndex
← Leaderboards

Xuejun Wang

University Of South Dakota

Google Scholar ↗PubMed ↗ORCID ↗
$17,526,818
Attributed
$20,344,154
Total exposure
12
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.5M · FY2005–25
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,344,154 · 12

By mechanism

R01$17,320,535 · 6
RF1$1,625,919 · 1
P20$947,678 · 4
R41$450,022 · 1

Top collaborators

Most similar at University Of South Dakota

Same institution · by research overlap

Others in their field

Top investigators on “Ubiquitin”

Research focus

UbiquitinProteinsHeartMulticatalytic Endopeptidase ComplexFunctional DisorderPreventCardiacQuality ControlHeart DiseasesMolecularMediatingCardiac MyocytesPlayPathway InteractionsLifeProtein DegradationCause Of DeathHeart FailureGenesDiagnosisClinical ManagementResearch Project GrantsHealthcareInnovation

Grant awards (56)

Cardiac Pathophysiology of Proteasome Phosphoregulation$698,466
R01 · FY2025 · HL · contact PI
Priming the proteasome to protect against aging and Alzheimer's disease$507,242
R01 · FY2025 · AG · contact PI
PKG and PKA Duo-Activation to Treat Cardiac Proteotoxicity$475,725
R01 · FY2023 · HL · contact PI
Cardiac Pathophysiology of Proteasome Phosphoregulation$367,500
R01 · FY2023 · HL · contact PI
Priming the proteasome to protect against aging and Alzheimer's disease$1,625,919
RF1 · FY2022 · AG · contact PI
PKG and PKA Duo-Activation to Treat Cardiac Proteotoxicity$484,772
R01 · FY2022 · HL · contact PI
Cardiac Pathophysiology of Proteasome Phosphoregulation$367,500
R01 · FY2022 · HL · contact PI
PKG and PKA Duo-Activation to Treat Cardiac Proteotoxicity$486,222
R01 · FY2021 · HL · contact PI
VAL-0914 Decreases PAO to Protect Against Cardiac Proteinopathies$450,022
R41 · FY2021 · HL
Cardiac Pathophysiology of Proteasome Phosphoregulation$367,500
R01 · FY2021 · HL · contact PI
PKG and PKA Duo-Activation to Treat Cardiac Proteotoxicity$496,540
R01 · FY2020 · HL · contact PI
Cardiac Pathophysiology of Proteasome Phosphoregulation$367,500
R01 · FY2020 · HL · contact PI
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$350,625
R01 · FY2020 · HL · contact PI
The COP9 Signalosome in the Heart$363,787
R01 · FY2019 · HL · contact PI
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$350,625
R01 · FY2019 · HL · contact PI
The COP9 Signalosome in the Heart$363,964
R01 · FY2018 · HL · contact PI
Ubiquitin receptors and cardiac proteotoxicity$362,500
R01 · FY2018 · HL · contact PI
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$350,625
R01 · FY2018 · HL · contact PI
The COP9 Signalosome in the Heart$364,132
R01 · FY2017 · HL · contact PI
Ubiquitin receptors and cardiac proteotoxicity$362,500
R01 · FY2017 · HL · contact PI
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$362,375
R01 · FY2017 · HL · contact PI
The COP9 Signalosome in the Heart$364,293
R01 · FY2016 · HL · contact PI
Ubiquitin receptors and cardiac proteotoxicity$362,500
R01 · FY2016 · HL · contact PI
Ubiquitin receptors and cardiac proteotoxicity$362,500
R01 · FY2015 · HL · contact PI
The COP9 SIgnalosome in the Heart$357,062
R01 · FY2015 · HL · contact PI
The COP9 SIgnalosome in the Heart$355,250
R01 · FY2014 · HL · contact PI
The COP9 SIgnalosome in the Heart$344,803
R01 · FY2013 · HL · contact PI
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$338,115
R01 · FY2013 · HL · contact PI
The COP9 SIgnalosome in the Heart$360,938
R01 · FY2012 · HL · contact PI
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$355,163
R01 · FY2012 · HL · contact PI
Proteasome, protein oxidation, and cardiomyocyte function.$410,661
R01 · FY2011 · HL
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$358,750
R01 · FY2011 · HL · contact PI
Proteasome, protein oxidation, and cardiomyocyte function.$414,499
R01 · FY2010 · HL
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$358,750
R01 · FY2010 · HL · contact PI
The COP9 Signalosome in the Heart$357,814
R01 · FY2010 · HL · contact PI
Proteasome, protein oxidation, and cardiomyocyte function.$411,788
R01 · FY2009 · HL
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$358,750
R01 · FY2009 · HL · contact PI
The COP9 Signalosome in the Heart$357,814
R01 · FY2009 · HL · contact PI
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$16,646
R01 · FY2009 · HL · contact PI
Proteasome, protein oxidation, and cardiomyocyte function.$400,292
R01 · FY2008 · HL
The COP9 Signalosome in the Heart$357,814
R01 · FY2008 · HL · contact PI
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE$161,793
P20 · FY2008 · RR · contact PI
The COP9 Signalosome in the Heart$357,814
R01 · FY2007 · HL · contact PI
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$333,048
R01 · FY2007 · HL · contact PI
The COP9 Signalosome in the Heart$378,625
R01 · FY2006 · HL · contact PI
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$342,996
R01 · FY2006 · HL · contact PI
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE$146,774
P20 · FY2006 · RR · contact PI
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$351,250
R01 · FY2005 · HL
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE$150,745
P20 · FY2005 · RR
SD COBRE: MOLECULAR BIOLOGY CORE$107,255
P20 · FY2005 · RR
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$351,250
R01 · FY2004 · HL
SD COBRE: UBIQUITIN-PROTEASOME IN CARDIAC REMODELING AND FAILURE$277,611
P20 · FY2004 · RR
CORE--SD COBRE: MOLECULAR BIOLOGY$103,500
P20 · FY2004 · RR
Molecular Pathogenesis of Protein Surplus Cardiomyopathy$351,250
R01 · FY2003 · HL
Core--Molecular biology$0
P20 · FY2002 · RR
The ubiquitin-proteasome system in cardiac remodeling$0
P20 · FY2002 · RR